Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported insider transactions dated 10/03/2025. Under a Rule 10b5-1 trading plan adopted on 12/12/2024, he exercised a stock option to acquire 10,000 shares at an exercise price of $9.15 per share and immediately sold 10,000 shares at a weighted-average price of $25.065 per share. The filings show the reporting person beneficially owned 21,831 shares before the sale and 11,831 shares after the sale; he also holds an option representing 10,000 underlying shares exercisable as of 10/03/2025 that expires on 03/14/2033, leaving 34,800 total shares and equivalents reported as beneficially owned following the transactions.
Stoke Therapeutics entered into an executive employment agreement and a change-of-control and severance agreement with Ian F. Smith effective October 6, 2025. The employment package includes a $500,000 sign-on bonus (repayable if Mr. Smith leaves or is terminated for cause within 12 months), a $500,000 performance bonus contingent on meeting specified metrics, an option to purchase 570,000 shares vesting 25% at one year then monthly over four years, and 380,000 restricted stock units vesting in four equal annual installments. If terminated without cause or for good reason within the defined change-of-control window, Mr. Smith would receive 18 months of continued base salary, 150% of annual target bonus in a lump sum, up to 18 months of healthcare premium payments, and 100% accelerated vesting of outstanding equity awards. The agreements reference an S-1 filed June 7, 2019.
STOK filed a Form 144 notice for the proposed sale of 42,461 shares of common stock through Morgan Stanley Smith Barney LLC, reflecting an aggregate market value of $1,053,882.02. The notice lists NASDAQ as the exchange with an approximate sale date of October 3, 2025.
The shares were acquired as restricted stock units on March 15, 2025. Shares outstanding were 54,797,418. Recent Rule 10b5‑1 activity by Edward Kaye over the prior three months included several sales, such as 45,996 shares on September 3, 2025 for $925,858.08 and 14,860 shares on September 2, 2025 for $299,259.60.
Stoke Therapeutics, Inc. (STOK) Form 144 notifies the SEC of a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on 10/03/2025 with an aggregate market value of $248,200.00. The filer reports the shares were acquired the same day on 10/03/2025 by exercise of stock options and paid for in cash. The filing also discloses multiple prior sales by the same person or plan during the past three months, including 15,000+ shares sold across dates in August and September 2025 generating gross proceeds such as $300,491.78 and $205,680.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references reliance on Rule 10b5-1 sales where applicable.
Stoke Therapeutics insider sale executed under a pre-established plan. Chief Medical Officer Barry Ticho sold 5,343 shares of common stock on 10/01/2025 at a weighted average price of $23.6414, with sale prices ranging from $23.40 to $24.08. After the transactions the reporting person beneficially owned 13,126 shares. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/11/2024, and the Form 4 was signed via attorney-in-fact on 10/03/2025.
Arthur A. Levin, Ph.D., a director of Stoke Therapeutics, reported equity awards and ownership changes on Form 4. On 09/30/2025 he became the beneficial owner of 1,211 restricted stock units (RSUs) that represent the right to receive one share each upon settlement. The filing shows these RSUs were recorded with a $0 price and are tied to settlement in common stock.
The report indicates 1,211 shares associated with the RSUs are held directly and that following the reported transaction the reporting person beneficially owned 3,631 shares directly and 17,979 shares indirectly through the Butler-Levin Revocable Trust, where he serves as trustee. The RSU award vests in quarterly 1/4 installments on the last day of March, June, September, and December, subject to continued service, with an indicated settlement date of 12/31/2025 for the reported tranche.
Stoke Therapeutics, Inc. filed an amended current report to disclose its decision on how often to hold non-binding advisory shareholder votes on executive compensation. Based on stockholder preferences expressed at the 2025 Annual Meeting and the Board’s prior recommendation, the company chose to hold Say-on-Pay votes every year.
The company plans to continue annual non-binding advisory Say-on-Pay votes until the next required Say-on-Frequency vote, which must occur no later than the 2031 Annual Meeting of Stockholders. No other changes were made to the previously reported 2025 Annual Meeting voting results.
Stoke Therapeutics, Inc. filed an amended current report to disclose its decision on how often to hold non-binding advisory shareholder votes on executive compensation. Based on stockholder preferences expressed at the 2025 Annual Meeting and the Board’s prior recommendation, the company chose to hold Say-on-Pay votes every year.
The company plans to continue annual non-binding advisory Say-on-Pay votes until the next required Say-on-Frequency vote, which must occur no later than the 2031 Annual Meeting of Stockholders. No other changes were made to the previously reported 2025 Annual Meeting voting results.
Stoke Therapeutics director Edward M. Kaye reported changes to his equity awards dated 09/04/2025. The filing shows an employee stock option covering 178,500 shares with an $8.33 exercise price was partially cancelled for no consideration under an exempt disposition, leaving 37,500 shares of common stock beneficially owned following the transaction. The option began vesting on April 15, 2025, and is scheduled to fully vest by December 15, 2026 if service continues. Separately, 144,000 restricted stock units were cancelled for no consideration; those RSUs had been scheduled to begin annual vesting on March 15, 2026. The report is filed on Form 4 and lists the reporting person as a director.
Stoke Therapeutics Chief Medical Officer Barry Ticho sold 5,501 shares of STOK common stock on 09/02/2025 under a Rule 10b5-1 trading plan adopted on 12/11/2024. The reported weighted-average sale price was $19.8737 per share, with individual trade prices ranging from $19.54 to $20.34 per share. After the reported sales, the reporting person beneficially owned 18,469 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Edward M. Kaye, MD, a director of Stoke Therapeutics (STOK), sold common stock in three transactions executed under a Rule 10b5-1 trading plan adopted December 30, 2024. The transactions show sales of 1,029 shares, 14,860 shares and 45,996 shares at weighted-average prices of $20.00 (single sale) and approximately $20.1386 and $20.1291 respectively. Following these reported sales the filing shows beneficial ownership of 91,585 shares, down from 152,441 shares after the first reported sale, reflecting a reduction of 60,856 shares in reported beneficial holdings. The filing discloses that the weighted-average sale prices ranged from $20.00 to $20.40 and that the reporting person will provide detailed per-price sale information on request.